Market
Market Share Impact on DraftKings/FanDuel from Antitrust Actions by Dec 31, 2025
2
Resolution / Starting Odds
DraftKings loses market share • 25%
FanDuel loses market share • 25%
Both lose market share • 25%
Neither loses market share • 25%
Market analysis reports, financial news, company disclosures
Story
Senators Request FTC, DOJ Probe Into DraftKings, FanDuel for Alleged Antitrust Violations
Dec 6, 2024, 04:22 PM
U.S. Senators Mike Lee and Peter Welch have requested an investigation by the Federal Trade Commission (FTC) and the Department of Justice (DOJ) into the online betting platforms DraftKings and FanDuel for potential violations of antitrust laws. The senators are concerned that these companies might be coordinating against competitors, following reports that they were allegedly pressuring businesses not to engage with competitors. DraftKings and FanDuel, major players in the online betting market, have seen their stocks, $DKNG and $FLUT respectively, affected by the news of the potential probe. The issue has bipartisan support, highlighting the growing scrutiny on the gambling industry's practices. Their merger was blocked in 2016 due to monopoly concerns.
View original story
Similar markets
No • 50%
Yes • 50%
Settlement reached • 25%
Other outcome • 25%
No action taken • 25%
Formal investigation launched • 25%
No • 50%
Yes • 50%
Increased competition • 25%
Other impact • 25%
No significant change • 25%
Decreased competition • 25%
Stock price decreases • 25%
Stock price increases • 25%
Insignificant impact • 25%
Stock price remains stable • 25%
Other • 25%
Remain stable (+/- 10%) • 25%
Decrease by more than 10% • 25%
Increase by more than 10% • 25%
Increase in customers • 25%
No significant change • 25%
Decrease in customers • 25%
Fluctuating customer numbers • 25%
Less than $15 billion • 25%
More than $25 billion • 25%
$20 billion to $25 billion • 25%
$15 billion to $20 billion • 25%
Major financial penalties • 25%
No significant impact • 25%
Minor financial penalties • 25%
Severe financial penalties • 25%
Negative reaction • 25%
Positive reaction • 25%
No significant reaction • 25%
Mixed reaction • 25%
Both gain equally • 25%
Neither gains market share • 25%
Novo Nordisk gains market share • 25%
Eli Lilly gains market share • 25%